[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gait-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gait-impairment":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,82,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100629226","robot-assisted-gait-training-vs-visual-feedback-balance-training-in-stroke-100629226",false,"NCT07471919","Robot-Assisted Gait Training vs Visual Feedback Balance Training in Stroke","Comparison of Robot-Assisted Gait Training and Visual Feedback Balance Training on Balance and Gait Outcomes in Patients With Stroke","Inclusion Criteria:\n\n* Age 21-85 years\n* Diagnosis of ischemic or hemorrhagic stroke confirmed by clinical and radiological findings\n* Functional Ambulation Category (FAC) ≥ 3\n* Modified Ashworth Scale ≤ 2 (lower extremity)\n* Ability to understand and follow simple verbal instructions\n* Mini-Mental State Examination (MMSE) score ≥ 23\n\nExclusion Criteria:\n\n* Unstable cardiopulmonary conditions\n* Severe musculoskeletal disorders affecting standing or walking\n* Severe aphasia preventing participation in assessments\n* Severe visual impairment interfering with balance testing","ALL","21 Years","85 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","Stroke frequently leads to balance impairment and gait dysfunction, increasing fall risk and limiting functional independence. Technology-assisted rehabilitation approaches such as robot-assisted gait training and visual feedback balance training have been shown to improve balance and mobility in stroke patients.\n\nThis randomized, assessor-blinded clinical trial aims to compare the effects of robot-assisted gait training and visual feedback balance training on balance and gait outcomes in patients with subacute and chronic stroke. Both interventions are part of routine clinical rehabilitation practice. Participants will be evaluated at baseline and after 4 weeks of intervention using clinical balance, gait, and functional assessments.",[27,28,29],"Stroke","Gait Impairment","Balance Impairment",[31,32,33,34,35],"Stroke rehabilitation","Robot-assisted gait training","Visual feedback balance training","Balance impairment","Gait impairment","RECRUITING","2026-08-17",{"date":39,"type":40},"2026-08-19","ACTUAL",{"date":42,"type":40},"2026-03-15",{"date":44,"type":21},"2026-08-15",{"name":46,"class":47},"Abant Izzet Baysal University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":67,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":48},"100650193","clinical-investigation-to-validate-the-safety-and-performance-of-the-able-kids-device-in-pediatric-patients-with-neurological-gait-disorders-in-a-clinical-setting-100650193","NCT07745712","Clinical Investigation to Validate the Safety and Performance of the ABLE Kids Device in Pediatric Patients With Neurological Gait Disorders in a Clinical Setting","Inclusion Criteria:\n\n* Minors with gait impairments, ranging from mild to severe, resulting from neurological conditions or muscular weakness\n* Anthropometric measurements compatible with the use of the exoskeleton, particularly:\n* Weight under 75 kg\n* Height between 1.0-1.5 m\n* Hip: maximum distance between greater trochanters of 35 cm\n* Thigh: maximum distance from trochanter to knee joint line of 36 cm\n* Lower leg: maximum distance from knee joint line to shoe sole of 45 cm\n* Medically stable\n* Intact skin in areas in contact with the device\n* Favorable medical assessment for standing, gait training, and weight-bearing activities\n* Signed informed consent from parents or legal guardians, and assent from the minor whenever possible, according to age and cognitive ability\n\nExclusion Criteria:\n\n* Severe spasticity in the lower limbs (MAS \\> 3)\n* Severe osteoporosis resulting in atraumatic bone fractures\n* Unhealed fractures or history of fragility fractures in the lower extremities within the past 2 years\n* Unstable or painful hip dislocation (MP \\> 50)\n* Symptomatic heterotopic ossification with mechanical limitation or pain\n* Anatomical limitations incompatible with proper fitting and safe use of the device:\n* Leg length discrepancy \\>1.5 cm in the upper segment or \\>2.0 cm in the lower segment\n* Severe scoliosis (Cobb angle \\>40° without the possibility of orthotic use during operation)\n* Inability to achieve proper adjustment within the device\n* Joint range of motion limitations preventing use of the exoskeleton:\n* Knee flexion contracture ≥40°\n* Hip flexion contracture ≥20°\n* Rigid equinus foot\n* Spine or lower extremity surgery within the last 3 months\n* Recently implanted pacemakers\n* Inability to communicate pain, fear, or discomfort (verbally or nonverbally)\n* Daytime mechanical ventilation\n* Uncontrolled epileptic seizures\n* Medical or cardiovascular instability\n* Considered unsuitable by physicians and physiotherapists. Any acute medical condition such as fever, infection, respiratory problems, urinary symptoms, uncontrolled pain, new swelling or redness in the extremities, active deep vein thrombosis, or severe comorbidities considered incompatible with the use of ABLE Kids until clinical resolution\n* Absence of head or trunk control in sitting or standing that cannot be compensated through the use of orthotic support during exoskeleton use","17 Years",{"count":57,"type":21},15,[24],"The primary objective of the study is to validate the safety and clinical performance of the ABLE Kids device in pediatric patients with neurological gait disorders or muscular weakness during a 10-session gait training program in a clinical setting.\n\nThe secondary objective of the study focuses on obtaining preliminary data on the potential clinical and psychosocial benefits of the product.",[28,61,62,63,64,65,66],"Aquired Brain Injury","Cerebral Palsy (CP)","Neuromuscular Diseases (NMD)","Spinal Cord Injuries (SCI)","Spina Bifida","Muscular Weakness",[68,69,70],"gait training","wearable exoskeleton","lower-limb exoskeleton","NOT_YET_RECRUITING","2026-07-30",{"date":74,"type":40},"2026-08-04",{"date":76,"type":21},"2026-09-01",{"date":78,"type":21},"2026-12-31",{"name":80,"class":81},"ABLE Human Motion S.L.","INDUSTRY",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":16,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100612434","vibrotactile-balance-belt-effect-on-improving-gait-100612434","NCT07253532","Vibrotactile Balance Belt Effect on Improving Gait","Impact of Vibrotactile Stimulation Via BalanceBelt and IMU-based Gait Analysis in Individuals With Balance Disorders","BalanceBelt","Inclusion Criteria:\n\n* Age 18-80 years old\n* Waist between 60 and 120 cm\n* Intact vibration sensitivity around the waist\n* Balance disorder and\u002For a diagnosis of ataxia or vestibular dysfunction (diagnosis based on imaging, clinical and family history, vestibular function tests, and\u002For genetic testing)\n* Speak English\n\nExclusion Criteria:\n\n* Previous Vestibular Rehabilitation Therapy (VRT) finished less than 2 months ago\n* Inability to stand or walk slowly without support in the light on a firm underground\n* Neurological, ophthalmological and\u002For orthopedic disorders that hampers vestibular, oculomotor or gait and posture examination",true,"18 Years","80 Years",{"count":94,"type":21},90,[24],"This study will examine the effect of using a vibrotactile feedback implemented into a belt, at improving gait in those with gait disorders.",[98,99,28],"Vestibular Hypofunction","Ataxia - Other","2026-03-23",{"date":102,"type":40},"2026-03-27",{"date":104,"type":40},"2026-03-20",{"date":106,"type":21},"2030-12-01",{"name":108,"class":47},"Johns Hopkins University",2,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":133,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":48},"100588304","bci-assisted-scs-exs-for-gait-optimization-100588304","NCT06939660","BCI-Assisted SCS-EXS for Gait Optimization","Spatiotemporal Spinal Cord Stimulation Based on Implantable Brain-machine Interfaces and Exoskeletons for Spinal Cord Injury (BASEGO)","BASEGO","Inclusion Criteria:\n\n* Age 14-65 years, any gender.\n* Clinical diagnosis of spinal cord injury (SCI) due to trauma, inflammation, tumor, vascular disease, or iatrogenic factors, confirmed by medical history, physical examination, and ancillary tests, resulting in lower limb motor dysfunction.\n* SCI diagnosed ≥6 months prior, with ≥1 month of continuous conventional rehabilitation (e.g., physical therapy, acupuncture, hydrotherapy, ≥3 hours daily) without significant improvement in motor function in the past 2 months.\n* ASIA Impairment Scale (AIS) grade A, B, or C based on the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI).\n* Good general health with a life expectancy ≥12 months.\n* Mini-Mental State Examination (MMSE) score ≥22.\n* Educational attainment of secondary school or above.\n* Willingness to participate, provide informed consent, and comply with study follow-up.\n\nExclusion Criteria:\n\n* Presence of diseases other than spinal cord injury (SCI) that affect lower limb motor function, including brain diseases (e.g., brain tumor, stroke), lower limb vascular diseases (e.g., lower limb vascular occlusion), peripheral nerve diseases, or lower limb bone diseases (e.g., osteoarthritis, joint contracture).\n* Requires continuous medical interventions (e.g., tracheal intubation, nasogastric feeding) to maintain critical physiological functions (e.g., heartbeat, respiration, swallowing).\n* Congenital or acquired structural abnormalities of the lower limb bones or muscles.\n* Presence of surgical contraindications (e.g., anesthesia-related adverse reactions, coagulation risks, or surgeon's determination of unsuitability for surgery).\n* Presence of active implantable devices except for SCS or BCI devices (e.g., pacemakers, defibrillators, drug infusion pumps, cochlear implants, sacral nerve stimulators).\n* Unable to receive implantable devices due to other disease treatments or investigations, or requires magnetic resonance imaging (MRI) during the device implantation period.\n* MRI shows structural damage \\>50% in motor function areas (precentral and postcentral gyri, ventromedial sensorimotor areas, mid temporal lobe, Broca's area, Wernicke's area, Geschwind's area), or DTI shows damage \\>50% in the posterior limb of the internal capsule.\n* Severe cardiovascular disease: Above level II myocardial ischemia or myocardial infarction, uncontrolled arrhythmias (including QTc interval ≥450 ms in men, ≥470 ms in women), level III-IV heart failure (NYHA classification), or echocardiography showing LVEF \\\u003C50%.\n* Coagulation abnormalities (INR \\>1.5 ULN, PT \\>ULN +4 s, or APTT \\>1.5 ULN), hemorrhagic tendency, or undergoing thrombolytic or anticoagulant therapy.\n* Severe infections within 4 weeks before surgery (requiring IV antibiotics, antifungals, or antivirals) or lumbar soft tissue infections, or unexplained fever \\>38.5℃ during screening or before surgery.\n* HIV infection, acquired immunodeficiency syndrome (AIDS), active tuberculosis, active hepatitis B (HBV DNA ≥500 IU\u002Fml), hepatitis C (positive HCV antibody and detectable HCV-RNA), or co-infection of hepatitis B and C.\n\nSevere cerebrovascular events (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, or pulmonary embolism within 12 months before enrollment.\n\n* Metastatic malignancies or untreated malignant tumors.\n* Major surgery or severe traumatic injuries, fractures, or ulcers within 4 weeks before enrollment.\n* Addictive habits such as drug abuse or alcoholism.\n* History of psychotropic drug abuse that is not controllable or presence of mental disorders, including major psychiatric illnesses (e.g., depression \\[BDI score \\>20\\], anxiety, obsessive-compulsive disorder, schizophrenia, autism, chronic sleep disorders, consciousness disorders).\n* Pregnant, breastfeeding, planning to conceive, or women of childbearing potential without reliable contraception.\n* Participation in other clinical trials within the past month.\n* Cognitive impairments or poor compliance from subjects, family members, or caregivers, or inability to complete at least 12 months of follow-up and rehabilitation training.\n* Other conditions that increase the risk of study participation or device use, as determined by the investigator.","14 Years","65 Years",{"count":121,"type":21},3,[24],"The goal of this clinical trial is to evaluate the safety and technical feasibility of a novel brain-machine interface (BCI)-assisted spinal cord stimulation (SCS) and exoskeleton (EXS) system in patients with spinal cord injury (SCI). The primary aim is to determine whether the BCI-SCS-EXS system can safely and effectively improve lower limb motor function and quality of life in individuals with chronic SCI.\n\nParticipant Population:\n\nAdults aged 14-65 years (sex\u002Fgender not limited). Patients with chronic SCI (≥6 months post-injury) classified as ASIA A, B, or C.\n\nIndividuals with stable health status, MMSE ≥22, and secondary education or above.\n\nPrimary Questions:\n\n1. Is the BCI-SCS-EXS system safe and technically feasible for SCI rehabilitation?\n2. Does the system improve lower limb motor function and quality of life in SCI patients?\n\nInterventions:\n\nParticipants will undergo the following procedures:\n\nPhase I (Implantation):\n\nBCI implantation: ECoG electrodes placed over the motor cortex to decode lower limb movement intent.\n\nSCS electrode implantation: 5-6-5 paddle electrodes at T11-L2 for targeted spinal cord stimulation.\n\nPhase II (System Calibration):\n\nBCI-SCS synchronization: Calibration of decoded motor intent to trigger SCS parameters.\n\nSCS-EXO synchronization: Integration of SCS pulses with exoskeleton-assisted gait training.\n\nPhase III (Rehabilitation):\n\nDaily BCI-SCS-EXS training sessions (60 minutes, 5 times\u002Fweek for 1 year). Adaptive adjustments to stimulation parameters and exoskeleton support based on performance.\n\nRemote monitoring of device performance and emergency intervention for technical issues.\n\nOutcome Measures:\n\nPrimary: Safety (adverse events, device performance, synchronization metrics). Secondary: Efficacy (motor function, neurophysiological function, quality of life).\n\nEthics and Safety:\n\nInformed consent will be obtained from all participants. Adverse events will be monitored and reported according to CTCAE 5.0 guidelines.\n\nParticipant confidentiality will be strictly maintained. This study will provide foundational evidence for the safety and feasibility of the BCI-SCS-EXO system, paving the way for future randomized controlled trials in SCI rehabilitation.",[64,125,126,127,128,129,130,131,132,28],"Spinal Cord Injury, Chronic","Spinal Cord Injury","Spinal Cord Injury Cervical","Spinal Cord Injury Thoracic","Spinal Cord Injury (Quadraplegia)","Motor Impairment","Motor Deficits","Gait Training",[134,135,136,137,138,139,140,141,142,143,144,145],"Brain-computer interface","Spianl cord stimulation","Exoskeleton","Rehabilitation","Spinal cord injury","Motor dysfunction","BCI","Brain-spinal interface","BSI","Brain-machine interface","Gait training","Neural plasticity","2025-05-14",{"date":148,"type":40},"2025-05-20",{"date":150,"type":40},"2025-04-23",{"date":152,"type":21},"2027-04-30",{"name":154,"class":47},"Xuanwu Hospital, Beijing"]